Key Highlights
- Evolus shares are up nearly 6% in pre-market trading after its Q2 2026 earnings report.
- Net revenue reached $84.1 million, up 21% year over year.
- The company posted its third consecutive quarter of positive adjusted EBITDA.
- Full-year 2026 revenue guidance was raised to a range of $330 million to $337 million.
- Evolus announced a new licensing deal for Letybo in additional international markets.
Revenue Growth Drives Shares Higher
Evolus is trading higher in pre-market action following a second-quarter report that showed accelerating growth and improving profitability. Shares rose as much as 5.69% to $6.53 in pre-market trading, building on a modest 0.98% gain in the prior regular session.
Net revenue for the quarter reached $84.1 million, up 21% year over year, driven by $75.2 million in global toxin revenue and $8.9 million in HA gel revenue. The results marked the company's third consecutive quarter of positive adjusted EBITDA, which came in at $4.7 million for the period.
Guidance Raised as Margins Improve
Management raised full-year 2026 revenue guidance to a range of $330 million to $337 million, with the midpoint implying growth of roughly 33.5%. The company also lifted its gross margin guidance to a range of 67.0% to 67.5% and narrowed its non-GAAP operating expense guidance, while reaffirming a low to mid single digit adjusted EBITDA margin outlook for the year.
Evolus also announced a strategic licensing agreement with Ipsen for Profilo, a skin quality category product expected to generate more than $100 million in peak annual revenue, alongside anticipated FDA approval around 2030. The deal expands Sinclair's participation in additional markets including Canada, Australia, and New Zealand, with U.S. launch planned by mid-2028.
About Evolus
Evolus is a performance beauty company headquartered in Newport Beach, California, focused on delivering breakthrough products in the cash-pay aesthetic market across the United States, Canada, Europe, and Australia. The company's flagship product, Jeuveau, is a proprietary 900 kilodalton purified botulinum toxin type A formulation approved for the temporary improvement of moderate to severe glabellar lines, commanding roughly 14% of the U.S. neuromodulator market.
Product Strategy and International Expansion
The company also highlighted continued momentum in its portfolio growth strategy, with purchasing across both Jeuveau and Evolyse showing 2.5 times greater volume than single-product accounts. International businesses tied to the Evolyse brand accounted for more than 10% of total revenue during the quarter. Looking further ahead, Evolus reaffirmed its long-term framework targeting $450 million to $500 million in annual revenue and 13% to 15% adjusted EBITDA margin by 2028, supported by a pipeline that includes Sculpt, expected to gain approval in the fourth quarter of 2026, and Evolyse Lips, which is expected to be submitted by year end.
Conclusion
Evolus delivered a strong second quarter marked by accelerating revenue growth, expanding margins, and continued momentum in its international expansion strategy. With raised full-year guidance and a growing product pipeline, the company appears on track toward its longer-term profitability targets.
Why is Evolus stock up today?
Evolus shares are trading higher after the company reported 21% year-over-year revenue growth in the second quarter of 2026 and raised its full-year guidance.
What was Evolus' revenue in Q2 2026?
The company reported net revenue of $84.1 million for the second quarter, up 21% from the same period a year earlier.
Did Evolus raise its full-year guidance?
Yes. The company raised its full-year 2026 revenue guidance to a range of $330 million to $337 million.
This article is for informational purposes only and does not constitute financial, investment, or trading advice. Readers should conduct their own research or consult a licensed financial advisor before making any investment decisions.






Please wait processing your request...